← Back to Search

NeuroVax for Multiple Sclerosis

Phase 2 & 3
Waitlist Available
Research Sponsored by Immune Response BioPharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 weeks
Awards & highlights

Study Summary

This trial is studying a vaccine called NeuroVax to see if it is better than a placebo at treating people with secondary progressive multiple sclerosis.

Eligible Conditions
  • Multiple Sclerosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The primary objective is to compare between treatment groups the cumulative number of new gadolinium enhancing (Gd+) lesions on brain MRI at up to 48 weeks in subjects with secondary progressive MS
Secondary outcome measures
Analyses of clinical relapses
Immunologic evaluations
Measures of neurologic disability EDSS score
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NeuroVaxExperimental Treatment1 Intervention
NeuroVax
Group II: IFA PlaceboPlacebo Group1 Intervention
IFA Placebo

Find a Location

Who is running the clinical trial?

Immune Response BioPharma, Inc.Lead Sponsor
4 Previous Clinical Trials
688 Total Patients Enrolled
2 Trials studying Multiple Sclerosis
162 Patients Enrolled for Multiple Sclerosis
croAMBIG
1 Previous Clinical Trials
150 Total Patients Enrolled
1 Trials studying Multiple Sclerosis
150 Patients Enrolled for Multiple Sclerosis
Richard M Bartholomew, Ph.DStudy DirectorImmune Response BioPharma, Inc.
2 Previous Clinical Trials
162 Total Patients Enrolled
2 Trials studying Multiple Sclerosis
162 Patients Enrolled for Multiple Sclerosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What other medical tests have used NeuroVax as a primary treatment?

"There are two ongoing clinical trials evaluating the efficacy of NeuroVax. One is in Phase 3 and both are based out of California, with one being in San Diego and the other having an unknown location."

Answered by AI

Who meets the requirements to participate in this experiment?

"This study is recruiting 200 individuals with multiple sclerosis that are between 18-50 years old. Most importantly, potential participants must meet the following conditions: Be diagnosed with MS using the revised McDonald criteria from 2005, have a secondary progressive course of the disease, an EDSS score of 3.5 or higher (Appendix B), have had two documented clinical relapses in MS in the past 24 months OR one relapse in the 12 months prior to screening , creatinine level 1 . 5x above normal, and hemoglobin levels within normal range."

Answered by AI

Are we still looking for volunteers for this experiment?

"The clinical trial, which was posted on March 9th 2020 and last updated on the same day, is presently looking for patients according to information available on clinicaltrials.gov"

Answered by AI

How many people are being treated as part of this clinical research?

"Yes, the trial is recruiting patients at this time. The original posting date was March 9th, 2020 and there have been no updates since then. They are looking for 200 participants from a single site."

Answered by AI

Have other medical studies like this been conducted before?

"NeuroVax was first studied in 2020 by Immune Response BioPharma, Inc. The Phase 2 & 3 drug approval followed the initial study of 200 patients. As of now, there are two active clinical trials involving NeuroVax being conducted across one city and one nation."

Answered by AI

Are people of all ages welcome in this clinical trial?

"This clinical trial has age restrictions of 18-50, as outlined in the inclusion criteria."

Answered by AI
~40 spots leftby Mar 2025